JP2016517434A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517434A5 JP2016517434A5 JP2016502844A JP2016502844A JP2016517434A5 JP 2016517434 A5 JP2016517434 A5 JP 2016517434A5 JP 2016502844 A JP2016502844 A JP 2016502844A JP 2016502844 A JP2016502844 A JP 2016502844A JP 2016517434 A5 JP2016517434 A5 JP 2016517434A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- composition according
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 26
- 150000003839 salts Chemical class 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 229940124597 therapeutic agent Drugs 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000003969 blast cell Anatomy 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 3
- -1 bidaza Chemical compound 0.000 claims 3
- 229960000975 daunorubicin Drugs 0.000 claims 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102100039489 Histone-lysine N-methyltransferase, H3 lysine-79 specific Human genes 0.000 claims 2
- 101000963360 Homo sapiens Histone-lysine N-methyltransferase, H3 lysine-79 specific Proteins 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000011987 methylation Effects 0.000 claims 2
- 238000007069 methylation reaction Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000008707 rearrangement Effects 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 102000006947 Histones Human genes 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 claims 1
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims 1
- 101150029107 MEIS1 gene Proteins 0.000 claims 1
- 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 claims 1
- 102000047831 Myeloid Ecotropic Viral Integration Site 1 Human genes 0.000 claims 1
- 208000006994 Precancerous Conditions Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000011132 hemopoiesis Effects 0.000 claims 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims 1
- 229950010895 midostaurin Drugs 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims 1
- 229950004847 navitoclax Drugs 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785446P | 2013-03-14 | 2013-03-14 | |
| US61/785,446 | 2013-03-14 | ||
| US201361900939P | 2013-11-06 | 2013-11-06 | |
| US61/900,939 | 2013-11-06 | ||
| US201361912872P | 2013-12-06 | 2013-12-06 | |
| US61/912,872 | 2013-12-06 | ||
| PCT/US2014/028609 WO2014153001A1 (en) | 2013-03-14 | 2014-03-14 | Combination therapy for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016517434A JP2016517434A (ja) | 2016-06-16 |
| JP2016517434A5 true JP2016517434A5 (enExample) | 2017-01-26 |
Family
ID=51581384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502844A Pending JP2016517434A (ja) | 2013-03-14 | 2014-03-14 | 癌を処置するための併用療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160045531A1 (enExample) |
| EP (1) | EP2968343A4 (enExample) |
| JP (1) | JP2016517434A (enExample) |
| AU (2) | AU2014236348B2 (enExample) |
| CA (1) | CA2903312A1 (enExample) |
| WO (1) | WO2014153001A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12331069B2 (en) | 2019-01-09 | 2025-06-17 | Dana-Farber Cancer Institute, Inc. | DOT1L degraders and uses thereof |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2882750A4 (en) | 2012-08-10 | 2016-08-17 | Epizyme Inc | INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF |
| EP2892536B1 (en) | 2012-09-06 | 2019-12-18 | Epizyme, Inc. | Method of treating leukemia |
| US9446064B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9738679B2 (en) | 2013-03-15 | 2017-08-22 | Epizyme, Inc. | Methods of synthesizing substituted purine compounds |
| US9493450B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| PE20161573A1 (es) | 2014-02-13 | 2017-01-19 | Incyte Corp | Ciclopropilamina como inhibidor de la lsd1 |
| WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016025635A2 (en) * | 2014-08-13 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2016043874A2 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2016090271A1 (en) * | 2014-12-05 | 2016-06-09 | Epizyme, Inc. | Treatment of leukemia via the administration of dot1l inhibitor pinometostat. |
| WO2016123626A1 (en) * | 2015-01-30 | 2016-08-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| EP3407978A4 (en) * | 2016-01-29 | 2020-01-15 | Epizyme Inc | POLYTHERAPY FOR THE TREATMENT OF CANCER |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| CN109748944B (zh) * | 2017-11-03 | 2021-12-10 | 中国科学院上海药物研究所 | 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN110092804A (zh) * | 2019-03-29 | 2019-08-06 | 广州盈升生物科技有限公司 | 一种含双环基团的嘌呤化合物及其制备方法 |
| CN114072407A (zh) | 2019-04-02 | 2022-02-18 | 阿里戈斯治疗公司 | 靶向prmt5的化合物 |
| US11285159B2 (en) | 2019-11-05 | 2022-03-29 | Abbvie Inc. | Dosing regimens for use in treating myelofibrosis and MPN-related disorders with navitoclax |
| CN113024620B (zh) * | 2021-03-11 | 2023-02-28 | 沈阳药科大学 | 一种嘌呤衍生物及其制备方法和用途 |
| AU2022306297A1 (en) | 2021-07-09 | 2024-02-08 | Plexium, Inc. | Aryl compounds and pharmaceutical compositions that modulate ikzf2 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US6998391B2 (en) * | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
| WO2004026319A2 (en) * | 2002-09-17 | 2004-04-01 | Centre National De La Recherche Scientifique | Pharmaceutical compositions increasing camp useful for the treatment of cancers |
| WO2009126537A1 (en) * | 2008-04-07 | 2009-10-15 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an hmt inhibitor |
| WO2012075492A2 (en) * | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | Carbocycle-substituted purine and 7-deazapurine compounds |
| CA2819648C (en) * | 2010-12-03 | 2018-05-01 | Epizyme, Inc. | Substituted purine and 7-deazapurine compounds |
| EP2646454B1 (en) * | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| DK2694510T3 (en) * | 2011-04-07 | 2016-01-18 | Bayer Ip Gmbh | IMIDAZOPYRIDAZINER AS AKT kinase inhibitors |
| EP2892536B1 (en) * | 2012-09-06 | 2019-12-18 | Epizyme, Inc. | Method of treating leukemia |
| US9446064B2 (en) * | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2016025635A2 (en) * | 2014-08-13 | 2016-02-18 | Epizyme, Inc. | Combination therapy for treating cancer |
-
2014
- 2014-03-14 EP EP14769036.6A patent/EP2968343A4/en not_active Withdrawn
- 2014-03-14 CA CA2903312A patent/CA2903312A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/028609 patent/WO2014153001A1/en not_active Ceased
- 2014-03-14 AU AU2014236348A patent/AU2014236348B2/en not_active Ceased
- 2014-03-14 JP JP2016502844A patent/JP2016517434A/ja active Pending
- 2014-03-14 US US14/776,669 patent/US20160045531A1/en not_active Abandoned
-
2018
- 2018-08-07 AU AU2018213995A patent/AU2018213995A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12331069B2 (en) | 2019-01-09 | 2025-06-17 | Dana-Farber Cancer Institute, Inc. | DOT1L degraders and uses thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517434A5 (enExample) | ||
| ES2762250T3 (es) | Tratamiento combinado del cáncer | |
| JP2020033360A5 (enExample) | ||
| JP2010511596A5 (enExample) | ||
| RU2012133528A (ru) | Способ лечения аутоиммунного демиелинизирующего заболевания центральной нервной системы (варианты) | |
| JP2012524112A5 (enExample) | ||
| CN102711686A (zh) | 含有低甲基化试剂以及组蛋白脱乙酰基酶抑制剂的药物组合物 | |
| JP2016517888A5 (enExample) | ||
| JP2011513437A5 (enExample) | ||
| JP2015532296A5 (enExample) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2013541583A5 (enExample) | ||
| JP2011500781A5 (enExample) | ||
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2016505050A5 (enExample) | ||
| JPWO2019241442A5 (enExample) | ||
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2019503335A (ja) | ジメチルアミノミケリオリドの使用 | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| CN102885840A (zh) | 淫羊藿苷在制备治疗支气管哮喘药物中的用途 | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| CN105078944A (zh) | Isopaucifloral F在制备抗骨质疏松药物中的用途 |